Compare JPMorgan Chase & Co (JPM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs TG Therapeutics Inc — how do they compare? JPMorgan Chase & Co trades at $345.15 (market cap $900.78B), while TG Therapeutics Inc trades at $54.31 (market cap $8.26B). The key difference: JPMorgan Chase & Co is far larger — about 109.1× TG Therapeutics Inc's market cap, and JPMorgan Chase & Co pays a 1.77% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| JPM | TGTX | |
|---|---|---|
Market Cap | $900.78B | $8.26B |
Volume | 10,479,943 | — |
Sector | Financials | Health |
52-Week High | $346.91 | $59.06 |
52-Week Low | $282.84 | $26.39 |
Dividend Yield | 1.77% | — |
Enterprise Value | — | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase (JPM) trades at $343.94, up 0.83% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth from $181.85B in 2025 to $194.8B projected for 2026. The stock shows robust fundamentals with a P/E of 14.52 and net income margin of 33.4%, though cash flow trends indicate significant investing outflows.
Outlook remains positive with a consensus price target of $372.73, implying ~8.4% upside. Risks include geopolitical tensions affecting oil markets and cybersecurity threats highlighted in recent news. Institutional ownership is stable, supporting a moderate buy rating amid economic uncertainties discussed by CEO Jamie Dimon.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
